{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:17:41Z","timestamp":1788232661335,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurosurg Rev"],"DOI":"10.1007\/s10143-026-04464-x","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:10:36Z","timestamp":1788232236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The role of stereotactic radiosurgery for prostate cancer spine metastasis - impact on hormone sensitivity and treatment outcomes: a systematic review of literature"],"prefix":"10.1007","volume":"49","author":[{"given":"Aaditya","family":"Dravid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suvan","family":"Sundaresh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Heesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Sanker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Akhavan-Sigari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Cavagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harminder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ratliff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atman","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"issue":"3","key":"4464_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"4464_CR2","volume-title":"Global Cancer Observatory: Cancer Today (GLOBOCAN 2022)","author":"International Agency for Research on Cancer (IARC)","year":"2024","unstructured":"International Agency for Research on Cancer (IARC) (2024) Global Cancer Observatory: Cancer Today (GLOBOCAN 2022). IARC, Lyon. Available from: Global Cancer Observatory platform"},{"issue":"3","key":"4464_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ph17030351","volume":"17","author":"A Bernal","year":"2024","unstructured":"Bernal A, Bechler AJ, Mohan K, Rizzino A, Mathew G (2024) The current therapeutic landscape for metastatic prostate cancer. Pharmaceuticals (Basel) 17(3):351. https:\/\/doi.org\/10.3390\/ph17030351","journal-title":"Pharmaceuticals (Basel)"},{"issue":"9","key":"4464_CR4","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1002\/jcb.23155","volume":"112","author":"MN Thobe","year":"2011","unstructured":"Thobe MN, Clark RJ, Bainer RO, Prasad SM, Rinker-Schaeffer CW (2011) Key players in prostate cancer bone metastasis. J Cell Biochem 112(9):2338\u20132345. https:\/\/doi.org\/10.1002\/jcb.23155","journal-title":"J Cell Biochem"},{"issue":"5","key":"4464_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(08)70089-9","volume":"7","author":"JS Cole","year":"2008","unstructured":"Cole JS, Patchell RA (2008) Metastatic epidural spinal cord compression. Lancet Neurol 7(5):459\u2013466. https:\/\/doi.org\/10.1016\/S1474-4422(08)70089-9","journal-title":"Lancet Neurol"},{"key":"4464_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12943-019-0990-6","volume":"18","author":"F La Manna","year":"2019","unstructured":"La Manna F, Karkampouna S, Zoni E, De Menna M, Hensel J, Thalmann GN et al (2019) Metastases in prostate cancer. Mol Cancer 18:56. https:\/\/doi.org\/10.1186\/s12943-019-0990-6","journal-title":"Mol Cancer"},{"issue":"6","key":"4464_CR7","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.3390\/cancers15061796","volume":"15","author":"M Esperan\u00e7a-Martins","year":"2023","unstructured":"Esperan\u00e7a-Martins M, Sousa B et al (2023) Multidisciplinary approach to spinal metastases and metastatic spinal cord compression: A comprehensive review. Cancers (Basel) 15(6):1796. https:\/\/doi.org\/10.3390\/cancers15061796","journal-title":"Cancers (Basel)"},{"key":"4464_CR8","unstructured":"National Institute for Health and Care Excellence (NICE). Spinal metastases and metastatic spinal cord compression: NICE guideline NG234. London: NICE (2023) Sep 6. Available from: NICE website"},{"issue":"10","key":"4464_CR9","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"E Schaeffer","year":"2023","unstructured":"Schaeffer E, Srinivas S, Antonarakis ES, Armstrong AJ, Bekelman JE, Cheng H et al (2023) Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 21(10):1067\u20131154","journal-title":"J Natl Compr Canc Netw"},{"issue":"7","key":"4464_CR10","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1470-2045(21)00196-0","volume":"22","author":"A Sahgal","year":"2021","unstructured":"Sahgal A, Myrehaug SD, Siva S, Masucci GL, Maralani PJ, Brundage MD et al (2021) Stereotactic body radiotherapy versus conventional external beam radiotherapy in patients with painful spinal metastases (SC.24): an open-label, multicentre, randomised, controlled, phase 2\/3 trial. Lancet Oncol 22(7):1023\u20131033. https:\/\/doi.org\/10.1016\/S1470-2045(21)00196-0","journal-title":"Lancet Oncol"},{"key":"4464_CR11","unstructured":"Lutz S, Balboni T, Jones J, Lo S, Petit J, Rich SE et al (2023) Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Pract Radiat Oncol. Available from: ASTRO Bone Metastases Guideline"},{"key":"4464_CR12","doi-asserted-by":"publisher","first-page":"1345053","DOI":"10.3389\/fonc.2024.1345053","volume":"14","author":"AN Sacino","year":"2024","unstructured":"Sacino AN, Patel AN, Oermann EK (2024) Stereotactic body radiation therapy for spinal metastases. Front Oncol 14:1345053. https:\/\/doi.org\/10.3389\/fonc.2024.1345053","journal-title":"Front Oncol"},{"issue":"6","key":"4464_CR13","doi-asserted-by":"publisher","first-page":"100989","DOI":"10.1016\/j.adro.2022.100989","volume":"7","author":"JJ Lucido","year":"2022","unstructured":"Lucido JJ et al (2022) Single and multifraction spine stereotactic body radiation therapy: spinal cord dose tolerance and radiation myelopathy risk. Adv Radiat Oncol 7(6):100989. https:\/\/doi.org\/10.1016\/j.adro.2022.100989","journal-title":"Adv Radiat Oncol"},{"key":"4464_CR14","unstructured":"Gal O et al (2024) Stereotactic body radiation therapy versus conventional external beam radiotherapy for spinal metastases: a systematic review and meta-analysis of randomized controlled trials. Pract Radiat Oncol"},{"key":"4464_CR15","first-page":"109999","volume":"196","author":"M Guckenberger","year":"2024","unstructured":"Guckenberger M et al (2024) ESTRO clinical practice guideline: Stereotactic body radiotherapy for oligometastatic disease. Radiother Oncol 196:109999 Guideline summarizes expected spinal SBRT LC\u2009~\u200980\u201390% at 1\u20132 years, with acceptable safety when constraints are respected","journal-title":"Radiother Oncol"},{"key":"4464_CR16","unstructured":"Guninski RS et al (2024) Efficacy and safety of stereotactic body radiotherapy for spine metastases: A systematic review. Radiother Oncol. (Systematic review reporting durable disease control and favorable toxicity profile across histologies.)"},{"key":"4464_CR17","doi-asserted-by":"crossref","unstructured":"Baron D et al (2023) Systemic therapy escalation after stereotactic body radiotherapy for oligometastatic hormone-sensitive prostate cancer. Cancer Med. (Supports MDT\/SBRT as a strategy associated with delaying escalation of systemic therapy in oligometastatic HSPC.)","DOI":"10.1016\/j.ctro.2023.100673"},{"issue":"6","key":"4464_CR18","first-page":"101279","volume":"9","author":"CJ Eule","year":"2024","unstructured":"Eule CJ et al (2024) Time to next systemic therapy after stereotactic body radiotherapy for oligoprogressive metastatic castration-resistant prostate cancer. Adv Radiat Oncol 9(6):101279 Demonstrates SBRT can delay next-line systemic therapy in oligoprogressive mCRPC","journal-title":"Adv Radiat Oncol"},{"key":"4464_CR19","unstructured":"Ruicci KM et al (2025) The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: a site-specific analysis. Radiother Oncol. (Supports SBRT for oligoprogressive disease as effective\/safe and reinforces rationale of delaying systemic progression\/escalation.)"},{"issue":"6","key":"4464_CR20","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.3390\/cancers15061701","volume":"15","author":"C Oing","year":"2023","unstructured":"Oing C, Rink M, Oechsle K, Bokemeyer C, Seidel C (2023) Systemic treatment of metastatic hormone-sensitive prostate cancer\u2014upfront triplet versus doublet therapy. Cancers (Basel) 15(6):1701. https:\/\/doi.org\/10.3390\/cancers15061701","journal-title":"Cancers (Basel)"},{"issue":"3","key":"4464_CR21","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jamaoncol.2020.6776","volume":"7","author":"L Wang","year":"2021","unstructured":"Wang L, Paller CJ, Hong H, Deek MP, Lopez-Corona E, Antonarakis ES (2021) Comparison of systemic treatments for metastatic castration-resistant prostate cancer: A systematic review and network meta-analysis. JAMA Oncol 7(3):412\u2013420. https:\/\/doi.org\/10.1001\/jamaoncol.2020.6776","journal-title":"JAMA Oncol"},{"issue":"19","key":"4464_CR22","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.3390\/jcm11195637","volume":"11","author":"L King","year":"2022","unstructured":"King L, Christie A, Siva S, Martin JM, Hovens CM, Lim Joon D et al (2022) Drivers of radioresistance in prostate cancer. J Clin Med 11(19):5637. https:\/\/doi.org\/10.3390\/jcm11195637","journal-title":"J Clin Med"},{"issue":"6","key":"4464_CR23","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1227\/neu.0000000000001909","volume":"90","author":"A Abugharib","year":"2022","unstructured":"Abugharib A, Zeng KL, Tseng CL, Soliman H, Myrehaug S, Husain Z et al (2022) Spine stereotactic body radiotherapy for prostate cancer metastases and the impact of hormone sensitivity status on local control. Neurosurgery 90(6):743\u2013749. https:\/\/doi.org\/10.1227\/neu.0000000000001909","journal-title":"Neurosurgery"},{"key":"4464_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s13014-021-01849-8","volume":"16","author":"P Rogowski","year":"2021","unstructured":"Rogowski P, Roach M, Schmidt-Hegemann NS, El Shafie R, Buchner A, Ilhan H et al (2021) Outcomes of metastasis-directed therapy of bone oligometastases in prostate cancer patients: a retrospective analysis. Radiat Oncol 16:128. https:\/\/doi.org\/10.1186\/s13014-021-01849-8","journal-title":"Radiat Oncol"},{"issue":"2","key":"4464_CR25","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.eururo.2023.10.021","volume":"86","author":"M Miszczyk","year":"2024","unstructured":"Miszczyk M, Soeterik T, Marra G, Matsukawa A, Shariat SF (2024) The efficacy and safety of metastasis-directed therapy in oligometastatic prostate cancer. Eur Urol 86(2):127\u2013139. https:\/\/doi.org\/10.1016\/j.eururo.2023.10.021","journal-title":"Eur Urol"},{"issue":"3","key":"4464_CR26","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11060-024-04821-0","volume":"170","author":"S Adida","year":"2024","unstructured":"Adida S, Taori S, Donohue JK, Rajan A, Sefcik RK, Burton SA, Flickinger JC, Gerszten PC (2024) Stereotactic radiosurgery for patients with spinal metastases from prostate cancer. J Neurooncol 170(3):631\u2013639. https:\/\/doi.org\/10.1007\/s11060-024-04821-0","journal-title":"J Neurooncol"},{"issue":"3","key":"4464_CR27","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3171\/2024.3","volume":"41","author":"TH Beckham","year":"2024","unstructured":"Beckham TH, Rooney MK, Cifter G, Bernard V, McAleer MF, De BS et al (2024) Stereotactic radiosurgery for prostate cancer spine metastases: local control and fracture risk using a simultaneous integrated boost approach. J Neurosurg Spine 41(3):436\u2013444. https:\/\/doi.org\/10.3171\/2024.3","journal-title":"J Neurosurg Spine"},{"key":"4464_CR28","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ctro.2016.12.001","volume":"4","author":"EW van Bouman-Wammes","year":"2017","unstructured":"Bouman-Wammes EW, van Dodewaard-De Jong JM, Dahele M, Cysouw MCF, Hoekstra O, van Moorselaar RJA et al (2017) Benefits of using stereotactic body radiotherapy in patients with metachronous oligometastases of hormone-sensitive prostate cancer detected by [18F]fluoromethylcholine PET\/CT. Clin Transl Radiat Oncol 4:14\u201319 https:\/\/doi.org\/10.1016\/j.ctro.2016.12.001. PMID:28462855","journal-title":"Clin Transl Radiat Oncol"},{"issue":"5","key":"4464_CR29","doi-asserted-by":"publisher","first-page":"e344","DOI":"10.1016\/j.prro.2024.04.022","volume":"14","author":"AJ Conde-Moreno","year":"2024","unstructured":"Conde-Moreno AJ, L\u00f3pez-Campos F, Herv\u00e1s A, Morillo V, M\u00e9ndez A, Puertas MDM et al (2024) Phase II trial of stereotactic body radiation therapy and androgen deprivation for oligometastases in prostate cancer (SBRT-SG 05). Pract Radiat Oncol 14(5):e344\u2013e352. https:\/\/doi.org\/10.1016\/j.prro.2024.04.022","journal-title":"Pract Radiat Oncol"},{"key":"4464_CR30","doi-asserted-by":"publisher","unstructured":"N\u00e4gler F, von der Gr\u00fcn J, Berthold D, Rack B, Rischke HC, Habl G et al (2025) Stereotactic body radiotherapy for spine and non-spine bone metastases in prostate carcinoma: a multicenter cohort analysis. J Bone Oncol. 100710. https:\/\/doi.org\/10.1016\/j.jbo.2025.100710. PMID:41019502","DOI":"10.1016\/j.jbo.2025.100710"},{"key":"4464_CR31","doi-asserted-by":"publisher","first-page":"109969","DOI":"10.1016\/j.radonc.2023.109969","volume":"190","author":"RS Guninski","year":"2024","unstructured":"Guninski RS, Cuccia F, Alongi F, Andratschke N, Belka C, Bellut D et al (2024) Efficacy and safety of stereotactic body radiotherapy for spine metastases: a systematic review and meta-analysis for preparation of an ESTRO practice guideline. Radiother Oncol 190:109969 https:\/\/doi.org\/10.1016\/j.radonc.2023.109969. PMID:37922993","journal-title":"Radiother Oncol"},{"issue":"6","key":"4464_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1634\/theoncologist.2012-0293","volume":"18","author":"I Laufer","year":"2013","unstructured":"Laufer I, Rubin DG, Lis E, Cox BW, Stubblefield MD, Yamada Y, Bilsky MH (2013) The NOMS framework: approach to the treatment of spinal metastatic tumors. Oncologist 18(6):744\u2013751. https:\/\/doi.org\/10.1634\/theoncologist.2012-0293","journal-title":"Oncologist"},{"issue":"12","key":"4464_CR33","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1097\/CORR.0000000000000946","volume":"477","author":"H Murtaza","year":"2019","unstructured":"Murtaza H, Saifi C, Vigdorchik J, Mroz TE (2019) Classifications in Brief: The Spinal Instability Neoplastic Score. Clin Orthop Relat Res 477(12):2799\u20132803. https:\/\/doi.org\/10.1097\/CORR.0000000000000946 PMID: 31658234; PMCID: PMC6907315","journal-title":"Clin Orthop Relat Res"},{"issue":"4","key":"4464_CR34","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.nec.2024.05.009","volume":"35","author":"X Zhang","year":"2024","unstructured":"Zhang X, Wang C, Bydon M, Sciubba DM (2024) Separation surgery for metastatic spine tumors. Neurosurg Clin N Am. 35(4):559\u2013569. https:\/\/doi.org\/10.1016\/j.nec.2024.05.009. PMID: 39430388","journal-title":"Neurosurg Clin N Am"},{"issue":"2","key":"4464_CR35","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.prro.2021.10.004","volume":"12","author":"S Faruqi","year":"2022","unstructured":"Faruqi S, Chen H, Fariselli L et al (2022) Stereotactic radiosurgery for postoperative spine malignancy: a systematic review and International Stereotactic Radiosurgery Society practice guidelines. Pract Radiat Oncol 12(2):e65\u2013e78. https:\/\/doi.org\/10.1016\/j.prro.2021.10.004","journal-title":"Pract Radiat Oncol"},{"issue":"4","key":"4464_CR36","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.nec.2024.05.010","volume":"35","author":"LG McVeigh","year":"2024","unstructured":"McVeigh LG, Sahgal A, Rhines LD et al (2024) Stereotactic body radiotherapy for treatment of spinal metastasis. Neurosurg Clin N Am 35(4):571\u2013584. https:\/\/doi.org\/10.1016\/j.nec.2024.05.010 PMID: 39430390; PMCID: PMC11485818","journal-title":"Neurosurg Clin N Am"},{"issue":"29","key":"4464_CR37","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek MP, Taparra K, Phillips R, Velho PI, Lim SJ, Deville C et al (2022) Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials. J Clin Oncol 40(29):3377\u20133382. https:\/\/doi.org\/10.1200\/JCO.22.00644 PMID:36001857","journal-title":"J Clin Oncol"},{"key":"4464_CR38","doi-asserted-by":"publisher","unstructured":"Patel P, Dreibe S, Attard G, Cole A, Diez P, Frew J, Guevara J et al (2025) Stereotactic body radiation therapy for oligoprogressive disease in androgen-suppressed prostate cancer: primary endpoint analysis of the TRAP trial. Int J Radiat Oncol Biol Phys. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.02.046","DOI":"10.1016\/j.ijrobp.2025.02.046"},{"issue":"5","key":"4464_CR39","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES et al (2020) Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol 6(5):650\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2020.0147","journal-title":"JAMA Oncol"},{"issue":"25","key":"4464_CR40","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C et al (2020) Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: Long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol 38(25):2830\u20132838. https:\/\/doi.org\/10.1200\/JCO.20.00818","journal-title":"J Clin Oncol"}],"container-title":["Neurosurgical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10143-026-04464-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10143-026-04464-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:10:43Z","timestamp":1788232243000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10143-026-04464-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4464"],"URL":"https:\/\/doi.org\/10.1007\/s10143-026-04464-x","relation":{},"ISSN":["1437-2320"],"issn-type":[{"value":"1437-2320","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"assertion":[{"value":"29 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. No approval from an Institutional Review Board (IRB) or Ethics Committee was required for this study.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve any human participants. Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was not a a clinical trial. Clinial trial number: not applicable.","order":4,"name":"Ethics","label":"Clinical trial registration","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"545"}}